Project Grant W81XWH2210278
- This Project Grant award, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports a transformative research project aimed at enhancing prostate cancer (PCA) prognostication through the integration of epithelial-to-mesenchymal transition (EMT) signature markers with advanced imaging and machine learning techniques. The $399,954 award to Metastx LLC will enable analysis of PCA tissue samples to develop a novel predictive model for metastatic...
- The U.S. National Cancer Institute (NCI) awarded a 5-year, $680,433 Project Grant to the University of California, San Francisco (UCSF) under the NCI's Cancer Detection and Diagnosis Research (CFDA 93.394) program. The grant supports research aimed at using cutting-edge spatial proteogenomic technologies and pathology artificial intelligence (PAI) to improve prognostic estimation and elucidate the underlying biology driving PAI outcomes in prostate cancer. The project seeks to: 1) understand the...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $603,981 to the University of Wisconsin-Madison to conduct research on integrated clinical-grade genomic and pathology artificial intelligence (AI) biomarkers for high-risk prostate cancer. The key objectives are to: 1) validate genomic and pathology AI as prognostic biomarkers for high-risk prostate cancer patients; 2) validate genomic and pathology AI as...
- The University of Miami was awarded a $538,553 federal Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to conduct longitudinal research on the use of quantitative multiparametric MRI (mpMRI) features and circulating tumor cells (CTCs) as early markers of treatment outcomes for prostate cancer patients receiving radiotherapy and androgen deprivation therapy (ADT). The goal of the 5-year research project is to define the role of mpMRI and...
- The National Cancer Institute awarded a $717,667 Project Grant titled "Artificial Intelligence Enabled Stroma-Weighted Automated Grading System to Improve Risk Stratification in Black Men" under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The grant aims to develop an AI-enabled automated grading system that leverages multiphoton microscopy and second harmonic generation imaging to analyze prostate cancer tumor biology and improve risk stratification, particularly...
- This Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $978,154 to Surgivance Inc. to further develop a digital pathology "laboratory-in-a-box" solution that produces and analyzes high-resolution, 3D digital pathology images at the point of care within seconds. The solution combines rapid confocal imaging hardware with AI-enabled software to automatically recolorize and interpret the digital...
- This National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) Project Grant award of $683,089 to the Sloan-Kettering Institute for Cancer Research supports the development of an improved, interpretable deep learning algorithm called DeepLIIF for more reproducible and accurate PD-L1 immunohistochemistry (IHC) biomarker quantification. The goal is to leverage virtual multiplex immunofluorescence (MPIF) restaining and large, diverse datasets across lung and bladder cancers to...
- The University of Delaware (UDE) has been awarded a $245,087 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop advanced AI-assisted prostate MRI interpretation capabilities. The project, titled "Integrating Radiologist Insights for Safe and Accurate AI-Assisted Prostate MRI Interpretation", aims to build on prior breakthroughs in image processing and natural language processing to create new AI tools for interpreting...
- This $681,215 federal Project Grant was awarded on September 1, 2025 by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to New York University (NYU) to develop AI-powered diagnostic tools for early prostate cancer detection. The project aims to leverage machine learning models to infer the presence of clinically significant prostate cancer using a minimal amount of degraded MRI data, in order to enable widespread, cost-effective population-level disease...
- This $194,022 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) supports research led by the Massachusetts General Hospital (MGH) to develop advanced deep learning models for predicting therapeutic response in cancer patients with brain metastases. The grant will fund the candidate, an oncologist at MGH, to build upon his expertise in...
HISTOMORPHOLOGICAL CHANGES ARE A DEFINING FEATURE IN EVERY CANCER TYPE. IN PC, HISTOPATHOLOGICAL ASSESSMENT OF PRIMARY TUMORS HAS BEEN PROVEN TO REVEAL THE MOST VALUABLE CLINICAL INFORMATION. HOWEVER, THE COMPLEX SPECTRUM OF HISTOLOGIES IN ADVANCED METASTATIC PC ARE DISTINCT FROM EARLIER STAGES OF DISEASE AND POORLY UNDERSTOOD. HERE WE PROPOSE THAT NOVEL DIGITAL MORPHOLOGY APPROACHES COUPLED WITH CUTTING-EDGE MACHINE LEARNING CAN DETERMINE HISTOLOGICAL FEATURES OF ADVANCED PC THAT INFORMS US ABOUT UNDERLYING MOLECULAR CHANGES AND CLINICAL BEHAVIOR. OBJECTIVE: WE HYPOTHESIZE THAT DEEP LEARNING BASED DIGITAL MORPHOLOGY ANALYSIS CAN OFFER NOVEL INSIGHTS INTO PC BIOLOGY AND IN COMBINATION WITH GENOMIC ANALYSIS CAN PROVIDE CLINICALLY RELEVANT INFORMATION. TO CRITICALLY TEST THIS HYPOTHESIS, WE HAVE COMPILED THE LARGEST SET OF METASTATIC PC SAMPLES TO DATE. WE WILL USE STATE OF THE ART MACHINE LEARNING APPROACHES AND DEVELOP NOVEL DATA INTEGRATION TOOLS TO ACCOMPLISH THE FOLLOWING SPECIFIC AIMS: SPECIFIC AIMS: AIM 1: GENERATE COMPREHENSIVE DIGITAL MORPHOLOGY ATLAS OF ADVANCED METASTATIC PC VIA TISSUE SOURCE AGNOSTIC PROCESSING PIPELINE. AIM 2: DETERMINE INTERACTIONS BETWEEN GENOMIC/EPIGENETIC ALTERATIONS AND TUMOR CELL MORPHOLOGY. AIM 3: DEVELOP INTEGRATED IMAGE-BASED AND GENOMIC BIOMARKERS FOR PATIENTS WITH ADVANCED PROSTATE CANCER. STUDY DESIGN: TO TRAIN MACHINE LEARNING ALGORITHMS TO ROBUSTLY DETECT HISTOMORPHOLOGICAL FEATURES IN METASTATIC PC, WE WILL FIRST DEVELOP A FRAMEWORK FOR NUCLEAR FEATURE EXTRACTION THAT IS ROBUST TO VARIATION IN TISSUE SOURCE, SITE, PROCESSING, AND STAINING CHARACTERISTICS. WE WILL THEN APPLY UNSUPERVISED AND SUPERVISED COMPUTER VISION APPROACHES TO GENERATE THE FIRST DIGITAL PATHOLOGY ATLAS OF METASTATIC PC AND ASSOCIATE MORPHOLOGICAL FEATURES WITH MOLECULAR PHENOTYPES. DEEP FEATURE EXTRACTION WILL BE CONSTRAINED BY EXPERTIN- THE-LOOP TRAINING TO ENABLE EXPLAINABLE, HUMAN-INTERPRETABLE DEEP LEARNING MODELS. NEXT, WE WILL ASSESS THE INTERPLAY BETWEEN GENOMIC/EPIGENETIC ALTERATIONS AND HISTOMORPHOLOGCIAL FEATURES USING LARGE MATCHED AND HARMONIZED GENOMIC, TRANSCRIPTOMIC, EPIGENETIC AND DIGITAL PATHOLOGY IMAGES DATASETS. THIS WILL ALLOW US TO GENERATE MODELS TO PREDICT GENOMIC/EPIGENETIC ALTERATION SIGNATURES FROM MORPHOLOGICAL FEATURES. FINALLY, WE WILL DETERMINE HISTOMORPHOLOGICAL FEATURES THAT ARE ASSOCIATED WITH CLINICAL OUTCOMES AND DERIVE A NOVEL INTEGRATED DIGITAL IMAGE ANALYSIS AND GENOMICS SCORE (IDIGS) WHICH WILL PROVIDE PREDICTIVE INFORMATION FOR PATIENTS WITH ADVANCED PC. IMPACT IN THIS STUDY WE WILL PERFORM THE LARGEST AND MOST COMPREHENSIVE ASSESSMENT OF HISTOMORPHOLOGICAL FEATURES OF METASTATIC PC TO DATE. WE USE FOR THE FIRST TIME AN INTEGRATED COMPREHENSIVE APPROACH TO STUDY MORPHOLOGICAL FEATURES AND RELATE THEM TO UNDERLYING MOLECULAR CHANGES. THESE EFFORTS WILL REVEAL IMPORTANT NEW INSIGHT INTO DISEASE BIOLOGY. ADDITIONALLY, DEEP LEARNING MODELS FOR MORPHOLOGICAL SEGMENTATION AND CLASSIFICATION WILL INTERFACE WITH PUBLICLY AVAILABLE VIEWING AND ANALYSIS TOOLS FOR FURTHER USE BY RESEARCHERS. FURTHERMORE, WE WILL LEVERAGE THESE INSIGHTS FOR BIOMARKER DEVELOPMENT, AND WE WILL INTRODUCE A NOVEL PREDICTIVE TOOL TO DETERMINE CLINICAL OUTCOMES IN MEN WITH METASTATIC PC. CONSEQUENTLY, THE PROPOSAL DIRECTLY ADDRESSES THE PCRP OVERARCHING CHALLENGE TO DEFINE THE BIOLOGY OF LETHAL PROSTATE CANCER TO REDUCE DEATH
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 7/21/25 | ||
| Not listed | $0 | 11/10/22 | ||
| Not listed | $0 | 7/25/22 | ||
| Not listed | $0 | 4/19/22 |